Price
No data yet.
Social Signal Score
Analyst Ratings
27 analystsRevenue
$490.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Evans
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 540
- Beta
- 2.20
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.88
Financials
Revenue
$490.0K+8066.7%Net Income
$-122.68MEBITDA
$-125.02MFree Cash Flow
$-68.51MEPS (diluted)
$-1.18Shares Outstanding (diluted)
104.33M+8110.0%Operating Expenses
$127.04MCash & Debt
$1.15BDividend per Share
$0.23Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $139.74M | $-79.99M | $-0.81 |
| 2024 | $63.52M | $-376.74M | $-4.58 |
| 2023 | $377.71M | $-132.53M | $-1.72 |
| 2022 | $60.92M | $-289.09M | $-4.13 |
| 2021 | $51.84M | $-370.64M | $-5.77 |
| 2020 | $24.0K | $-194.59M | $-5.49 |
| 2019 | $18.0K | $-78.33M | $-1.53 |
| 2018 | $0.00 | $-115.26M | $-3.28 |
| 2017 | $0.00 | $-8.73M | $-0.62 |
Valuation
BEAMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
43-39.29%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·9d ago·Neutral
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while Risto-cel's blockbuster potential is now downgraded. AI-driven competition, such as Anthropic, is unlikely to disrupt BEAM in the near term; partnerships with AI firms could become a future catalyst.
View source ↗ - Newsbusinesswire.com·22d ago·Negative
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $BEAM--BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsseekingalpha.com·29d ago·Positive
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newszacks.com·30d ago·Neutral
3 Promising Genomics Stocks in the Spotlight in 2026 Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
View source ↗ - Newsseekingalpha.com·30d ago·Positive
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-30…
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
View source ↗ - Newszacks.com·45d ago·Positive
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-1.16 per share
Typical surprise -4.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.18 vs $-1.11miss
- Thu, May 7$-0.91 vs $-0.87miss
- Tue, Feb 24$-0.10 vs $-1.13beat
- Tue, Nov 4$-1.10 vs $-0.98miss
- Tue, Aug 5$-1.00 vs $-1.04beat
- Tue, May 6$-1.24 vs $-1.11miss
Estimates and results for BEAM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BEAM officers and directors.
- Bought
- —
- Sold
- $22.2m
0 trades
43 trades
- Cavanagh Bethany Jsold
- Simon Amysold
- Simon Amysold
- Evans John M.sold
- Evans John M.sold
- Evans John M.sold
- Evans John M.sold
- Fmr Llcsold
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BEAM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.